Trials / Completed
CompletedNCT02131636
Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 440 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of AGN-199201 once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-199201 | AGN-199201 applied to the face once daily for 29 days. |
| DRUG | Vehicle to AGN-199201 | Vehicle to AGN-199201 applied to the face once daily for 29 days. |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2014-11-01
- Completion
- 2014-12-01
- First posted
- 2014-05-06
- Last updated
- 2019-11-18
- Results posted
- 2016-03-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02131636. Inclusion in this directory is not an endorsement.